Screener / SEC EDGAR /CIK 0001639691 /10-K filed Feb 25, 2026, compared with Feb 25, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Medical Devices

LivaNova PLC LIVN

Compare with peers Embed
What it said it expected, against what it reported

No target with a reported result yet

Releases of the last 3 years

The numbers LIVN said it expected, in its earnings releases, next to what it then reported for the same period.

Target by target

Each target, with the sentence it came from · release and 10-Q or 10-K

The last range givenReported, abovewithin or keptbelow or missed
TargetWhat the company saidReportedResult
Free cash flow (company-defined)
Fiscal 2026
Given $160.00M to $180.00M release Feb 25, 2026
Kept $160.00M to $180.00M release May 6, 2026
Lowered $140.00M to $160.00M release Aug 5, 2026
Kept $140.00M to $160.00M release Nov 4, 2026
– No standard number
The company's words
Issues 2026 Guidance … Adjusted free cash flow is expected to be in the range of $160 million to $180 million release Feb 25, 2026
Maintained full-year 2026 adjusted free cash flow range of $160 million to $180 million release May 6, 2026
Lowered full-year 2026 adjusted free cash flow range to $140 million to $160 million release Aug 5, 2026
Maintained full-year 2026 adjusted free cash flow range of $140 million to $160 million release Nov 4, 2026
Diluted EPS (company-defined)
Fiscal 2026
Given $4.15 to $4.25 release Feb 25, 2026
Raised $4.20 to $4.30 release May 6, 2026
Raised $4.30 to $4.40 release Aug 5, 2026
Raised $4.40 to $4.50 release Nov 4, 2026
– No standard number
The company's words
– Issued full-year 2026 guidance, including constant-currency revenue growth between 6.0% and 7.0% and adjusted diluted earnings per share in the range of $4.15 to $4.25 – Received increased provider reimbursement from U.S. Centers for Medicare & Medicaid Services for VNS Therapy for Drug-Resistant Epilepsy procedures, effective Jan. 1, 2026, significantly reducing a known barrier to procedure penetration – Received U.S. Food and Drug Administration approval for cloud-based digital health platform release Feb 25, 2026
Adjusted diluted earnings per share for 2026 is now expected to be in the range of $4.20 to $4.30 (versus $4.15 to $4.25 prior), assuming a share count of approximately 56 million for full-year 2026. release May 6, 2026
Adjusted diluted earnings per share for 2026 is now expected to be in the range of $4.30 to $4.40 (versus $4.20 to $4.30 prior), assuming a share count of approximately 56 million for full-year 2026. release Aug 5, 2026
Adjusted diluted earnings per share for 2026 is now expected to be in the range of $4.40 to $4.50 (versus $4.30 to $4.40 prior), assuming a share count of approximately 56 million for full-year 2026. release Nov 4, 2026
Free cash flow (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $135.00M to $155.00M release Feb 25, 2025
Kept $135.00M to $155.00M release May 7, 2025
Raised $140.00M to $160.00M release Aug 6, 2025
Raised $160.00M to $180.00M release Nov 5, 2025
– No standard number
The company's words
Issues 2025 Guidance London, February 25, 2025 … Adjusted free cash flow is expected to be in the range of $135 million to $155 million release Feb 25, 2025
In 2025, the Company continues to estimate that adjusted free cash flow will be in the range of $135 million to $155 million. release May 7, 2025
In 2025, the Company now estimates adjusted free cash flow in the range of $140 million to $160 million (versus $135 million to $155 million prior). release Aug 6, 2025
In 2025, the Company now estimates adjusted free cash flow in the range of $160 million to $180 million (versus $140 million to $160 million prior). release Nov 5, 2025
Diluted EPS (company-defined)
Fiscal 2025 (ended Dec 31, 2025)
Given $3.65 to $3.75 release Feb 25, 2025
Lowered $3.60 to $3.70 release May 7, 2025
Raised $3.70 to $3.80 release Aug 6, 2025
Raised $3.80 to $3.90 release Nov 5, 2025
– No standard number
The company's words
Adjusted diluted earnings per share for 2025 is expected to be in the range of $3.65 to $3.75. release Feb 25, 2025
Revised full- year 2025 adjusted diluted earnings per share range to $3.60 to $3.70, which now incorporates the impact of the SNIA decision and currently applicable tariffs. release May 7, 2025
Adjusted diluted earnings per share for 2025 is now expected to be in the range of $3.70 to $3.80 (versus $3.60 to $3.70 prior), assuming a share count of approximately 55 million for full-year 2025. release Aug 6, 2025
Adjusted diluted earnings per share for 2025 is now expected to be in the range of $3.80 to $3.90 (versus $3.70 to $3.80 prior), assuming a share count of approximately 55 million for full-year 2025. release Nov 5, 2025
Free cash flow (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $95.00M to $115.00M release Feb 21, 2024
Kept $95.00M to $115.00M release May 1, 2024
Kept $95.00M to $115.00M release Jul 31, 2024
Raised $110.00M to $130.00M release Oct 30, 2024
– No standard number
The company's words
In 2024, the Company estimates that adjusted free cash flow will be in the range of $95 to $115 million. release Feb 21, 2024
In 2024, the Company continues to estimate that adjusted free cash flow will be in the range of $95 to $115 million. release May 1, 2024
For 2024, the Company continues to estimate that adjusted free cash flow will be in the range of $95 to $115 million. release Jul 31, 2024
For 2024, the Company now estimates that adjusted free cash flow will be in the range of $110 to $130 million. release Oct 30, 2024
Diluted EPS (company-defined)
Fiscal 2024 (ended Dec 31, 2024)
Given $2.95 to $3.05 release Feb 21, 2024
Raised $3.05 to $3.15 release May 1, 2024
Raised $3.10 to $3.20 release Jul 31, 2024
Raised $3.30 to $3.40 release Oct 30, 2024
– No standard number
The company's words
Adjusted diluted earnings per share for 2024 are expected to be in the range of $2.95 to $3.05, assuming a share count of approximately 55 million for full-year 2024. release Feb 21, 2024
Adjusted diluted earnings per share for 2024 are now expected to be in the range of $3.05 to $3.15, assuming a share count of approximately 55 million for full- year 2024. release May 1, 2024
Adjusted diluted earnings per share for 2024 is now expected to be in the range of $3.10 to $3.20, assuming a share count of approximately 55 million for full- year 2024. release Jul 31, 2024
Adjusted diluted earnings per share for 2024 is now expected to be in the range of $3.30 to $3.40, assuming a share count of approximately 55 million for full- year 2024. release Oct 30, 2024

Targets are read from the sentences of the EX-99 exhibits of 8-K item 2.02 filings (12 releases since 2024-02-21), without AI; in outlook tables only the first column is read. The result compares the reported number with the last range given before the period was reported. Results come from SEC's XBRL company facts, as first reported. A company's target can use its own definition (META's capital expenditures include finance lease payments, for example), so read the quote.

Sources

The outlook sentences of each earnings release (8-K item 2.02, exhibit 99), read without AI; results from SEC's XBRL company facts, as first reported.

Also

Earnings releases: each release in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/LIVN/export.csv") into a cell.

Next:Archive
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.